These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 33358362)

  • 1. Use of Immune Checkpoint Inhibitors in Early Triple-Negative Breast Cancer: Beyond the Early Conflicting Results.
    Ammad Ud Din M; Jamshed S; Patel M
    Clin Breast Cancer; 2021 Jun; 21(3):153-155. PubMed ID: 33358362
    [No Abstract]   [Full Text] [Related]  

  • 2. Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials.
    Hall PE; Schmid P
    Expert Opin Emerg Drugs; 2021 Jun; 26(2):131-147. PubMed ID: 33870839
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.
    Kwa MJ; Adams S
    Cancer; 2018 May; 124(10):2086-2103. PubMed ID: 29424936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1/PD-L1 counterattack alliance: multiple strategies for treating triple-negative breast cancer.
    Zhu H; Du C; Yuan M; Fu P; He Q; Yang B; Cao J
    Drug Discov Today; 2020 Sep; 25(9):1762-1771. PubMed ID: 32663441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Checkpoint inhibitors in breast cancer: hype or promise?
    McArthur HL
    Clin Adv Hematol Oncol; 2016 Jun; 14(6):392-5. PubMed ID: 27379806
    [No Abstract]   [Full Text] [Related]  

  • 7. Towards targeting the breast cancer immune microenvironment.
    Harris MA; Savas P; Virassamy B; O'Malley MMR; Kay J; Mueller SN; Mackay LK; Salgado R; Loi S
    Nat Rev Cancer; 2024 Aug; 24(8):554-577. PubMed ID: 38969810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single peptides and combination modalities for triple negative breast cancer.
    Razazan A; Behravan J
    J Cell Physiol; 2020 May; 235(5):4089-4108. PubMed ID: 31642059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.
    Liu J; Liu Q; Li Y; Li Q; Su F; Yao H; Su S; Wang Q; Jin L; Wang Y; Lau WY; Jiang Z; Song E
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evolving role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer.
    Steiner M; Tan AR
    Clin Adv Hematol Oncol; 2021 May; 19(5):305-315. PubMed ID: 33989278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Navigating practical challenges in immunotherapy for metastatic triple negative breast cancer.
    Licata L; Dieci MV; De Angelis C; Marchiò C; Miglietta F; Cortesi L; Fabi A; Schmid P; Cortes J; Pusztai L; Bianchini G; Curigliano G
    Cancer Treat Rev; 2024 Jul; 128():102762. PubMed ID: 38776613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Radionuclide Therapy and Immunotherapy for Treatment of Triple Negative Breast Cancer.
    Vito A; Rathmann S; Mercanti N; El-Sayes N; Mossman K; Valliant J
    Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34063642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Blockade in Patients with Triple-Negative Breast Cancer.
    Michel LL; von Au A; Mavratzas A; Smetanay K; Schütz F; Schneeweiss A
    Target Oncol; 2020 Aug; 15(4):415-428. PubMed ID: 32514907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenging immune exhaustion in early recurrent triple-negative breast cancer: pitfalls and hopes.
    Tarantino P; Tolaney SM
    Ann Oncol; 2024 Jul; 35(7):579-581. PubMed ID: 38910014
    [No Abstract]   [Full Text] [Related]  

  • 15. Checkpoint inhibitors in breast cancer - Current status.
    Polk A; Svane IM; Andersson M; Nielsen D
    Cancer Treat Rev; 2018 Feb; 63():122-134. PubMed ID: 29287242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer.
    Yuan SJ; Xu YH; Wang C; An HC; Xu HZ; Li K; Komatsu N; Zhao L; Chen X
    J Nanobiotechnology; 2019 Oct; 17(1):110. PubMed ID: 31623629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedside.
    Abdel-Aziz AK; Saadeldin MK; D'Amico P; Orecchioni S; Bertolini F; Curigliano G; Minucci S
    Eur J Cancer; 2019 Nov; 122():22-41. PubMed ID: 31606656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Where do the immune checkpoint inhibitors stand in the management of triple negative breast cancer?
    Rassy EE; Karak FE; Ghosn M
    Immunotherapy; 2018 Feb; 10(4):247-250. PubMed ID: 29421978
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: A new clinical paradigm in the treatment of triple-negative breast cancer.
    Cyprian FS; Akhtar S; Gatalica Z; Vranic S
    Bosn J Basic Med Sci; 2019 Aug; 19(3):227-233. PubMed ID: 30915922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.